Please assess the completion status of the following clinical trial:

Trial Title: Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged from 2 to 45 years on the day of inclusion.~* Participant in good health, based on medical history and physical examination.~* Provision of informed consent form (and assent form for participants aged 6 to 12 years) signed by the participant and by the parent(s) or another legally acceptable representative for participants aged less than 21 years.~* Participants and parent(s)/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.~* For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks before the first vaccination until 4 weeks after the last vaccination.~Exclusion Criteria :~* Febrile illness (temperature \>= 37.5°C) or moderate or severe acute illness/infection on the day of the first vaccination, according to Investigator judgment.~* For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of inclusion.~* Breast-feeding woman.~* Known systemic hypersensitivity to any of the components of the trial vaccines (especially egg proteins or neomycin) or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.~* Personal or family history of thymic pathology or myasthenia.~* Previous hepatitis A vaccination (for children only).~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or long-term systemic corticosteroid therapy.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the 18 coming months.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.~* Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Current or past alcohol abuse or drug addiction that may interfere with the participants ability to comply with trial procedures.~* Participant who plans to move to another country within the 18 coming months.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine Group (Type: EXPERIMENTAL): Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
- Placebo Group (Type: SHAM_COMPARATOR): All participants received a placebo at first vaccination (Month 0). Participants \<12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants \>= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).